Optimizing Research with Decentralized Strategies
DECENTRALIZED, DIGITALLY ENABLED, DIRECT-TO-PATIENT
Biopharma and biotech organizations are increasingly opting for decentralized or hybrid trial designs over traditional solutions. In addition, sites and patients have become more tech savvy and knowledgeable of alternative trial modes resulting in a heavier reliance on technology such as televisits, remote eConsent, eCOA, remote monitoring, wearables and virtual sites to reduce delays and mitigate risk during unpredictable times.
PPD® Digital works closely with leading research organizations around the world to navigate evolving trends in drug development, including the design and deployment of customized, remote clinical trials. PPD has been a guiding force in the industry, bringing long-standing expertise and establishing best practices for study teams embarking on new modes of clinical research.
READY FOR REAL TRANSFORMATION?
Insights from PPD on the vitality of clinical trials during the pandemic – including metrics, services, technologies, and the changes that virtual clinical trials bring.
WHAT YOU NEED TO KNOW TODAY
Increasingly, sponsors see decentralization not just as an immediate risk-mitigation tactic, but as a highly effective, comprehensive approach to conduct clinical trials under any circumstances. Digital clinical trials can enhance investigator site interactions and boost convenience for patients, allowing continued participation in trials regardless of local regulations, or unexpected life events.
As a known leader in the decentralized trial (DCT) space, PPD routinely publishes detailed insights into these solutions. With so many clinical technologies emerging, our experts help you sift through the noise and determine what is most meaningful to know for your research.